More than 900 Biologics in Development - - BioPharm International

ADVERTISEMENT

More than 900 Biologics in Development



America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report (PDF) released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

The report includes biologics in human clinical trials or under review by FDA such as 338 cancer therapeutics that target several different types of solid tumors, leukemia and lymphoma; 134 vaccines for infectious diseases; 71 medicines for autoimmune diseases including lupus, multiple sclerosis, and rheumatoid arthritis; and 58 treatments for cardiovascular disease.

Among the biologic medicines in development are a genetically-modified virus-based vaccine to treat melanoma; a monoclonal antibody for the treatment of asthma; an antisense therapy for the treatment of leukemia; a recombinant fusion protein to treat Type II diabetes.

The report lists the product name, sponsor, product category, indication, and development phase.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

UPS' Pain in the Supply Chain Results
September 23, 2014
Merck KGaA Announces Acquisition of Sigma-Aldrich for $17 Billion
September 22, 2014
Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
Author Guidelines

Click here